Skip to content
value.today

Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is listed today as Dermata Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Dermata Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$4 MPrivate placement after listing$2 to $10 million

Dermata Therapeutics, Inc.: Private sale, Dec 2025

Investors in this round

14 investors had bought by the notice of Jan 7, 2026: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Dermata Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$342,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Nardo · Executive Officer
  • Gerald Proehl · Executive Officer, Director
  • Kyri K. Van Hoose · Executive Officer
  • Maria J. Bedoya Toro Munera · Executive Officer
  • Andrew J. Sandler · Director
  • Brittany J. Bradrick · Director
  • David J. Hale · Director
  • Kathleen J. Scott · Director
  • Mary J. Fisher · Director
  • Steven J. Mento · Director
  • Wendell J. Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Includes a cash fee of 7% of gross proceeds from outside investors and 3.5% from inside investors, 1% management fee, $25,000 non-accountable expense allowance, and $40,000 accountable expense allowance.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Gerald Proehl, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 7, 2026. Read the notice at the SEC.

equity, optionsSEC
Jan 2025$3 MPrivate placement after listing$2 to $10 million

Dermata Therapeutics, Inc.: Private sale, Jan 2025

Investors in this round

8 investors had bought by the notice of Feb 4, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Dermata Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$174,751
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Nardo · Executive Officer
  • Gerald Proehl · Executive Officer, Director
  • Kyri K. Van Hoose · Executive Officer
  • Maria J. Bedoya Toro Munera · Executive Officer
  • Andrew J. Sandler · Director
  • Brittany J. Bradrick · Director
  • David J. Hale · Director
  • Kathleen J. Scott · Director
  • Mary J. Fisher · Director
  • Steven J. Mento · Director
  • Wendell J. Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Includes a cash fee equal to 7% of the aggregate gross proceeds raised from outside institutional investors and 3.5% of the aggregate gross proceeds raised from insider investors, a management fee of 1% and a non-accountable expense allowance of $25,000.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Gerald Proehl, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 4, 2025. Read the notice at the SEC.

equity, optionsSEC
Sep 2024$4 MPrivate placement after listing$2 to $10 million

Dermata Therapeutics, Inc.: Private sale, Sep 2024

Investors in this round

1 investor had bought by the notice of Sep 27, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Dermata Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$345,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Nardo · Executive Officer
  • Gerald Proehl · Executive Officer, Director
  • Kyri K. Van Hoose · Executive Officer
  • Maria J. Bedoya Toro Munera · Executive Officer
  • Andrew J. Sandler · Director
  • Brittany J. Bradrick · Director
  • David J. Hale · Director
  • Kathleen J. Scott · Director
  • Mary J. Fisher · Director
  • Steven J. Mento · Director
  • Wendell J. Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Includes a cash fee received of $245,000, $35,000 (management fees), $25,000 (non-accountable expense), $40,000 (legal) and warrants to purchase 133,880 shares of common stock.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Gerald Proehl, Chief Executive Office. Source: SEC Form D, newest notice filed Sep 27, 2024. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dermata Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jan 2026

That is all the official record says: Dermata Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Dermata Therapeutics, Inc. are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Dermata Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Proehl Investment Ventures LLCVenture capitalnot statednot statedHeld preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Wendell WierengaPersonnot statednot statedHeld preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Dermata Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dermata Therapeutics, Inc.
NameRoleNamed in
Christopher J. NardoExecutive officerJan 2026
Gerald ProehlExecutive officerJan 2026
Kyri K. Van HooseExecutive officerJan 2026
Maria J. Bedoya Toro MuneraExecutive officerJan 2026
Andrew J. SandlerDirectorJan 2026
Brittany J. BradrickDirectorJan 2026
David J. HaleDirectorJan 2026
Gerald ProehlDirectorJan 2026
Kathleen J. ScottDirectorJan 2026
Mary J. FisherDirectorJan 2026
Steven J. MentoDirectorJan 2026
Wendell J. WierengaDirectorJan 2026

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.